

Hanoi, March 31st, 2025**ANNOUNCEMENT OF 2024 FINANCIAL STATEMENTS****Respectfully to:** - State Securities Commission

- Hanoi Stock Exchange

Pursuant to:

- Legal Regulations on Information Disclosure in the Securities Market;
- 2024 Financial Statements of Viet Nam Medicinal Materials Joint Stock Company;
- Self-prepared financial reports for the quarters of 2024.

Viet Nam Medicinal Materials Joint Stock Company (Stock code: DVM) would like to announce information regarding the fluctuations in profit for 2024 compared to 2023, as well as the discrepancies between the audited financial statements for 2024 and the previously published self-prepared reports, as follows:

1. The fluctuations in profit for 2024 compared to 2023:

Content	Code	Current year	Prior year	Increase/decrease value	Increase/decrease rate (%)
1	2	4	5	6	7
1. Revenue from goods sold and services rendered	01	1,580,015,291,142	1,482,341,922,333	97,673,368,809	6.59
2. Deductions	02	46,032,000	622,238,801	(576,206,801)	-92.60
3. Net revenue from goods sold and services rendered (10 = 01 - 02)	10	1,579,969,259,142	1,481,719,683,532	98,249,575,610	6.63
4. Cost of goods sold	11	1,439,371,590,106	1,323,480,020,325	115,891,569,781	8.76
5. Gross profit from goods sold and services rendered (20 = 10 - 11)	20	140,597,669,036	158,239,663,207	(17,641,994,171)	-11.15
6. Financial incomes	21	4,592,777,323	6,130,105,302	(1,537,327,979)	-25.08



7. Financial expenses	22	47,700,455,832	58,874,378,815	(11,173,922,983)	-18.98
- In which: Interest expense	23	47,700,455,832	58,874,378,815	(11,173,922,983)	-18.98
8. Selling expenses	25	11,254,728,685	25,672,546,257	(14,417,817,572)	-56.16
9. General and Administrative expenses	26	28,419,639,298	30,829,595,637	(2,409,956,339)	-7.82
10. Profit from operating activities (30 = 20 + (21 - 22) - 25 - 26)	30	57,815,622,544	48,993,247,800	8,822,374,744	18.01
11. Other income	31	764,986,315	655,912,019	109,074,296	16.63
12. Other expenses	32	3,179,149,538	152,891,592	3,026,257,946	1979.35
13. Other profit (40 = 31 - 32)	40	(2,414,163,223)	503,020,427	(2,917,183,650)	-579.93
14. Profit before tax (50 = 30 + 40)	50	55,401,459,321	49,496,268,227	5,905,191,094	11.93
15. Current corporate income tax expense	51	7,526,574,665	6,333,919,392	1,192,655,273	18.83
16. Deferred corporate income tax expense	52		0		0.00
17. Profit after corporate income tax (60 = 50 - 51 - 52)	60	47,874,884,656	43,162,348,835	4,712,535,821	10.92

- The after-tax profit in the audited financial statements for 2024 increased by 4,712,535,821 VND, equivalent to 10.92% compared to the previous year due to the following reasons:

- ✓ Revenue in 2024 increased by 97 billion VND compared to 2023; however, the cost of goods sold also increased by 98 billion VND as pharmaceutical products with high cost prices accounted for a large proportion of revenue.
- ✓ Financial expenses decreased.
- ✓ Selling expenses decreased as the company focused on wholesale channels, major distributors, and hospitals, minimizing retail channels.
- ✓ Administrative expenses decreased by 2.4 billion VND, mainly due to a reduction in salaries and related labor costs.

Best regards./.

Recipients:

- *As above;*
- *Archived at the office.*

GENERAL DIRECTOR



VU THANH TRUNG

